Hyperion Therapeutics

Hyperion Therapeutics, Inc. is a privately held specialty biopharmaceutical company founded in 2006 to improve patients’ lives through the development and commercialization of therapies that address critical unmet needs and underserved patient populations. The Company is focused on becoming a global leader in gastrointestinal and hepatology therapeutic programs and products.

Hyperion aims to build a portfolio of products through partnership, in-licensing, and/or internal development efforts. In August, 2007, through a strategic collaboration with Ucyclyd Pharma, Inc. (a subsidiary of Medicis Pharmaceutical Corporation), Hyperion obtained sales and marketing responsibilities for the only two FDA-approved medications indicated as adjunctive therapy in the management of urea cycle disorders (UCDs). As part of this agreement, Hyperion is also continuing the research and development of two compounds with a primary focus on treating UCDs and hepatic encephalopathy (HE). If these products and uses are approved by the FDA, Hyperion will commercialize them as well.

Hyperion is led by a seasoned executive team with extensive experience developing and commercializing specialty pharmaceutical products.